Sight Sciences (SGHT) announced the results of a cost-utility analysis, CUA, assessing the cost-effectiveness of the TearCare System compared to cyclosporine 0.05%, CsA, for the treatment of moderate to severe meibomian gland disease, MGD, associated dry eye disease, DED. The analysis, published ahead of print in Expert Review of Pharmacoeconomics and Outcomes Research, demonstrated that TearCare is not only associated with greater health utility over time but also resulted in significant cost savings compared to CsA, offering a more efficient and patient-centric approach to treating this common ocular disease. Key Findings: Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an incremental QALY gain of 0.014, compared to those on CsA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences announces publication of 24-month results of SAHARA RCT
- Sight Sciences price target raised to $4 from $3 at Morgan Stanley
- Sight Sciences price target raised to $4 from $3.50 at Piper Sandler
- Sight Sciences: Hold Rating Amid Promising TearCare Potential and Market Access Challenges
- Sight Sciences Holds Annual Stockholders Meeting